- Official launch in March with support of local partner Talia Medical -

Humedix, an aesthetics-focused subsidiary of Huons Group, is targeting the Middle East market with three hyaluronic acid (HA) fillers under its Elravie Plus brand. 

On the 12th, Humedix’s (CEO Kang Min-Jong) announced that the company has recently obtained regulatory approval in Syria for three products: ‘Elravie Deep Line Plus 1ml’, ‘Elravie Ultra Volume Plus 2ml’ and ‘Elravie Light Plus 1ml’.

The company plans to launch the three Elravie Plus fillers in the Syrian market in March. For this market entry, Humedix has partnered with Talia Medical LLC, a local company specializing in the importation and distribution of medical devices and aesthetic products in Syria.

Leveraging its local network and in-depth market understanding, Talia Medical will support a stable supply chain and a smooth market entry for the three Elravie Plus fillers. Through this partnership, Humedix aims to provide high-quality HA fillers to medical professionals and consumers in Syria.

Humedix has previously secured regulatory approvals for its Elravie-branded products and currently markets them in multiple countries, including Brazil, China, Thailand, Russia, and Iraq. With the approval of this product in Syria, the company aims to further expand its presence in the Middle East. Humedix stated that it will continue to accelerate its global market entry by strengthening its product portfolio and steadily increasing the number of countries in which its products are launched.

Humedix CEO Kang Min-jong said, “The Syrian approval for three types of Elravie Plus fillers will serve as a crucial stepping stone for expanding our global market presence. We will continue providing safe and reliable aesthetic solutions and actively pursue market entry strategies, including in the Middle East.”